QUADRA: A phase 2, open-label, single-arm study to evaluate niraparib in patients (pts) with relapsed ovarian cancer (ROC) in 4th or later line of...

Date 20 October 2018
Event ESMO 2018 Congress
Session Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Topics Ovarian Cancer
Anticancer Agents
Personalised/Precision Medicine
Presenter Kathleen Moore
Citation Annals of Oncology (2018) 29 (suppl_8): viii332-viii358. 10.1093/annonc/mdy285
Authors K.N. Moore1, A.A. Secord2, M. Geller3, D.S. Miller4, N.G. Cloven5, G.F. Fleming6, A.E. Wahner Hendrickson7, M. Azodi8, P. DiSilvestro9, A. Oza10, M. Cristea11, J.S. Berek12, J.K. Chan13, B.J. Rimel14, Y. Li15, K. Luptakova16, R. Clark16, U.A. Matulonis17, B.J. Monk18
  • 1Gynecologic Oncology, Stephenson Cancer Center, University of Oklahoma, 73104 - Oklahoma City/US
  • 2Gynecologic Oncology, Duke University Medical Center, Duke Cancer Institute, Durham/US
  • 3Obstetrics, Gynecology And Women's Health, University of Minnesota Medical School, Minneapolis/US
  • 4Obstetrics & Gynecology, University of Texas Southwestern Medical Center, 75390-8576 - Dallas/US
  • 5Gynecologic Oncology, Texas Oncology - FortWorth, Fort Worth/US
  • 6Gynecologic Oncology, The University of Chicago Medicine, 60637-1470 - Chicago/US
  • 7Medical Oncology, Mayo Clinic, 55905 - Rochester/US
  • 8Obstetrics, Gynecology & Reproductive Sciences, Smillow Cancer Hospital at Yale and Yale University, New Haven/US
  • 9Gynecologic Oncology, Women and Infants Hospital, Providence/US
  • 10Medical Oncology And Hematology, University Health Network and Princess Margaret Cancer Centre, Toronto/CA
  • 11Medical Oncology & Therapeutics Research, City of Hope National Medical Center, Duarte/US
  • 12Obstetrics & Gynecology, Stanford Women's Cancer Center, Stanford/US
  • 13Gynecologic Oncology, Sutter Health, San Francisco/US
  • 14Obstetrics And Gynecology, Cedars-Sinai Medical Center, West Hollywood/US
  • 15Biostatistics, TESARO, Inc., Waltham/US
  • 16Clinical Science, TESARO, Inc., Waltham/US
  • 17Medical Oncology, Harvard Medical School, Boston/US
  • 18Division Of Gynecologic Oncology, Arizona Oncology (US Oncology Network), University of Arizona College of Medicine, Phoenix Creighton University School of Medicine at St. Joseph's Hospital, 85013 - Phoenix/US



Therapeutic options in late line ROC offer limited efficacy, especially for pts who are considered platinum (plat) resistant (res) or refractory (ref). Pts whose cancers harbor BRCA mutations (BRCAmut) have been included in poly (ADP-ribose) polymerase inhibitor (PARPi) trials and derived modest benefit from treatment (ORR ≈25% for plat-res and 0-14% for plat-ref pts). QUADRA evaluated niraparib monotherapy in ROC pts regardless of their plat and biomarker status.


Eligible pts received treatment with single agent niraparib in 4th or later line of therapy. Pts were evaluated for BRCAmut and HRD status (MyChoice HRD Test). Pts received niraparib 300 mg once daily until progression; treatment emergent adverse events (AEs) were managed with dose reduction to 200 or 100 mg. The primary endpoint was ORR per RECIST v1.1.


463 pts were treated. Median age was 65 years (range: 29-91). 162 pts were plat ref (defined as progression within 28 days of the last dose of plat); 152 plat res (defined as less than 6 months between last dose of plat and subsequent progression); 118 plat sensitive; 31 unknown. Results in HRD+ pts have been presented at a prior congress. We focus here on the tBRCAmut (both germline and somatic) PARPi-naïve subgroup. ORR for 4th line or later, PARPi-naïve tBRCAmut pts (n = 55) was 31% (95% CI: 19-45), including 18 plat-sensitive pts (ORR 39%), 21 plat-res pts (ORR 33%), and 16 plat-ref pts (ORR 19%). The combined ORR in the plat-res and -ref pts (n = 37) was 27%. The median DOR among all tBRCAmut pts was 9.2 months, with an estimated 43% of responding pts maintaining their response at 24 months. In the entire study cohort, 197 pts (42.5%) experienced a serious AE (SAE) and 91 pts (19.7%) a treatment-related SAE. The most frequent treatment-emergent SAEs were gastrointestinal disorders (19.9%), thrombocytopenia (8.4%), small intestinal obstruction (6.6%), and vomiting (5.1%).


Niraparib demonstrated meaningful and durable responses among the difficult-to-treat patient population, including platinum resistant and refractory tBRCAmut patients.

Clinical trial identification


Legal entity responsible for the study

Tesaro, Inc.


Tesaro, Inc.

Editorial Acknowledgement

Writing and editorial support, funded by Tesaro, Inc. (Waltham, MA, USA) and coordinated by Ted Paunescu, PhD of TESARO, Inc., was provided by Nicole Renner, PhD and Dena McWain of Ashfield Healthcare Communications (Middletown, CT, USA).


K.N. Moore: Honorarium and served on advisory boards: Tesaro, Genentech Roche, Clovis, Astra Zeneca (for agents not involved in the SOLO-a Study), Immunogen, VBL Therapeutics, Janssen. M. Geller: Advisory Role, Speakers' bureau & Research funding: Tesaro Inc. D.S. Miller: Advisory role: Eisai, ImmunoGen, Tesaro, Clovis Oncology, Genentech, AstraZeneca, Guardant Health, Alexion. Speakers' bureau: Genentech, Clovis; Research funding: Tracon, AstraZeneca, Tesaro, Janssen, Aeterna Zentaris, Genentech, Pfizer, Aprea AB, ImmunoGen, Takeda, Xenetic Biosciences. N.G. Cloven: Employment: Texas Oncology. G.F. Fleming: Research funding: Corcept Therapeutics. P. DiSilvestro: Advisory role: Tesaro, AstraZeneca; Research funding: AstraZeneca, Tesaro, Abbvie, Genentech, Roche, Janssen. A. Oza: Steering Committees for PARPi trials: Tesaro, Clovis, AstraZeneca; Honoraria: Intas Pharma. M. Cristea: Research funding: Trovagene. J.S. Berek: Advisory role: Atara Biotherapeutics; Research funding: Tesaro. J.K. Chan: Advisory role: Roche/Genentech, AstraZeneca, Janssen Oncology, Clovis, Mateon, Biodesix, Tesaro; Spearkers' bureau and Honoraria: Roche/Genentech, AstraZeneca, Clovis, Tesaro. Y. Li, K. Luptakova, R. Clark: Employment and stock and other ownership interests: Tesaro Inc. U.A. Matulonis: Advisory role: Merck KGaA, AstraZeneca, Immunogen, Tesaro, Genentech. B.J. Monk: Advisory role: GSK, Merck, Tesaro, Roche/Genentech, AstraZeneca,Gradalis, Advaxis, Verastem, Cerulean Pharma, Amgen, Vermillion, Immunogen, Bayer, NuCana BioMed, Insys Therapeutics, Clovis, Oxigene, Pfizer, Mateon, Precision, Perthera, Biodesix, Abbvie, Myriad, Incyte; Spearkers' bureau: Roche/Genentech, AstraZeneca, Janssen, Clovis, Tesaro; Honoraria: GSK, Merck, Tesaro, Roche/Genentech, AstraZeneca, Gradalis, Advaxis, Veraste, Cerulean, Amgen Vermillion, Bayer, NuCana BioMed, Insys Therapeutics, Clovis, Oxigene, Pfizer Mateon, Precision, Perthera, Biodesix, Abbvie, Myriad, Incyte, Janssen. All other authors have declared no conflicts of interest.